78 completed, 12 recruiting, 10 active not recruiting, 9 terminated. 59 Phase 3, 25 Phase 1, 17 Phase 2, 3 Not applicable, 3 Phase 4.
By phase and status
Phase Trials Status Phase 3 59 Completed 39 , Active not recruiting 10 , Recruiting 5 , Not yet recruiting 3 , Terminated 2 Phase 1 25 Completed 15 , Recruiting 5 , Terminated 3 , Enrolling by invitation 1 , Unknown 1 Phase 2 17 Completed 13 , Recruiting 2 , Terminated 1 , Unknown 1 Not applicable 3 Completed 2 , Terminated 1 Phase 4 3 Terminated 2 , Completed 1
Follow Chugai Pharmaceutical: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications Enicepatide, Tirzepatide - Type 2 Diabetes Mellitus Phase 3 Not yet recruiting Hoffmann-La Roche 948 2026-12-01 2026-10-22 Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children NXT007 - Hemophilia A Phase 3 Not yet recruiting Hoffmann-La Roche 50 2026-11-30 2026-10-19 A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Afimkibart, Placebo - Moderately to Severely Active Ulcerative Colitis Phase 3 Not yet recruiting Hoffmann-La Roche 350 2026-11-15 2026-09-29 AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer AQUA07, Lorlatinib - ALK Positive Non-small Cell Lung Cancer Phase 1 Recruiting Chugai Pharmaceutical 102 2026-07-24 2026-09-18 A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A NXT007, Human Coagulation Factor VIII - Hemophilia A Phase 3 Recruiting Hoffmann-La Roche 138 2026-05-15 2026-09-23 A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A NXT007, Emicizumab - Hemophilia A Phase 3 Recruiting Hoffmann-La Roche 360 2026-04-27 2026-10-06 Study of DONQ52 in Active Celiac Disease Placebo DONQ52, Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52 - Celiac Disease Phase 2 Recruiting Chugai Pharmaceutical 92 2025-12-16 2026-08-14 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Divarasib, Pembrolizumab, Pemetrexed - Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer Phase 3 Recruiting Hoffmann-La Roche 600 2025-10-24 2026-10-06 A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER ALPS12, obinutuzumab - Extensive Stage Small Cell Lung Cancer Phase 1 Recruiting Chugai Pharmaceutical 122 2025-10-08 2026-02-06 Study of AUBE00 in Patients With Solid Tumors AUBE00, Cetuximab - Solid Tumors Phase 1 Recruiting Chugai Pharmaceutical 130 2025-06-05 2026-09-29 A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease Afimkibart, Placebo - Moderately to Severely Active Crohns Disease Phase 3 Recruiting Hoffmann-La Roche 425 2025-05-12 2026-09-28 A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease Afimkibart, Placebo - Moderately to Severely Active Crohns Disease Phase 3 Recruiting Hoffmann-La Roche 600 2025-03-17 2026-10-16 Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) Phase 1 Enrolling by invitation Chugai Pharmaceutical 144 2024-12-09 2026-07-17 A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Divarasib, Sotorasib, Adagrasib - Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer Phase 3 Active not recruiting Hoffmann-La Roche 338 2024-09-23 2026-09-16 A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Afimkibart, Placebo - Moderately to Severely Active Ulcerative Colitis Phase 3 Active not recruiting Hoffmann-La Roche 400 2024-09-17 2026-09-14 Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC Induction therapy - Metastatic Breast Cancer Phase 2 Recruiting Japan Breast Cancer Research Group 106 2024-09-13 2025-01-30 Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) Phase 1 Recruiting Chugai Pharmaceutical 144 2024-08-19 2026-07-22 A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 RO7496353, Atezolizumab, Capecitabine - Non-small Cell Lung Cancer, Gastric Cancer Phase 1 Completed Genentech, Inc. 102 2023-10-02 2026-06-18 A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) Atezolizumab, Bevacizumab, Tiragolumab - Hepatocellular Carcinoma Phase 3 Active not recruiting Hoffmann-La Roche 687 2023-09-14 2025-12-31 A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors ROSE12, Atezolizumab, Pembrolizumab - Solid Tumor Phase 1 Recruiting Chugai Pharmaceutical 209 2023-05-24 2026-07-28
Showing 20 of 116. Sign in to see all of them.
Conditions studied Arthritis, Rheumatoid (12) · Breast Neoplasms (10) · Hemophilia A (7) · Carcinoma, Non-Small-Cell Lung (6) · Arthritis, Juvenile (4) · Carcinoma, Hepatocellular (3) · Celiac Disease (3) · Colorectal Neoplasms (3) · Hemoglobinuria, Paroxysmal (3) · Hepatitis C, Chronic (3) · Lung Neoplasms (3) · Neoplasms (3) · Neuromyelitis Optica (3) · Anemia (2) · Antiphospholipid Syndrome (2)
Interventions tocilizumab (14) · Bevacizumab (8) · atezolizumab (7) · satralizumab (7) · Capecitabine (6) · Paclitaxel (5) · emicizumab (5) · Cisplatin (4) · Letrozole (4) · Fluorouracil (3) · Oxaliplatin (3) · PCO371 (3) · Trastuzumab (3) · continuous erythropoietin receptor activator (3) · peginterferon alfa-2a (3)
Countries Japan (68) · United States (46) · France (33) · Germany (27) · Italy (27) · Spain (25) · Taiwan (25) · Poland (24) · South Korea (23) · Brazil (21) · Australia (20) · United Kingdom (20) · Canada (17) · China (16) · Hungary (15)
Top investigators Takahiro Kakehi (11) · Takanori Baba (6) · Yuji Kimura (3) · Yoshiharu Ishikura (2) · Akihito Tsuji, M.D., Ph.D. (1) · Anna Minchom, MB BCh, FRCP, MD (Res) (1) · Eric Hedrick, MD (1)
Results publications PMID 35939785 , PMID 18358927 , PMID 24634205 , PMID 24786929 , PMID 36007339 , PMID 36724181 , PMID 38280653 , PMID 39535306 , PMID 40288333 , PMID 40743487 , PMID 40978458 , PMID 42014371 , PMID 42753135 , PMID 20728210 , PMID 21784190 , PMID 21844504 , PMID 22116464 , PMID 22247354 , PMID 22508806 , PMID 22794117 , PMID 23955585 , PMID 24062399 , PMID 24942210 , PMID 24951609 , PMID 25038874 , PMID 26929219 , PMID 27324280 , PMID 27482854 , PMID 28120036 , PMID 28249150 , PMID 28619014 , PMID 28691557 , PMID 29753033 , PMID 29791011 , PMID 30157389 , PMID 30877202 , PMID 31003963 , PMID 31136632 , PMID 31401903 , PMID 31697801 , PMID 31774956 , PMID 31978221 , PMID 32333898 , PMID 32703200 , PMID 32943098 , PMID 33128873 , PMID 33301930 , PMID 34019214 , PMID 35304832 , PMID 35405087
NIH funding 2023 (8), 2016 (4), 2015 (2), 2025 (2), 2019 (1)